探索灯盏细辛注射液临床用药的合理性与安全性  

To explore the rationality and safety of clinical medication of Erigeron breviscapus injection

作　　者：黄雪钦 陈苑兰 陈素惠 Huang Xueqin;Chen Yuanlan;Chen Suhui(Heyuan Yuancheng District People's Hospital,Heyuan,Guangdong 517000,China)

机构地区：[1]广东省河源市源城区人民医院,广东河源517000

出　　处：《首都食品与医药》2023年第4期80-83,共4页Capital Food Medicine

摘　　要：目的 探讨灯盏细辛注射液临床用药的合理性与安全性.方法 回顾性分析2021年1月-2021年12月河源市源城区人民医院120例接受灯盏细辛注射液治疗的患者临床资料,系统收集患者临床治疗资料(疾病类型、病情、病程、灯盏细辛注射液用药剂量及方法等)以及基本资料(年龄、性别等),结合患者资料与灯盏细辛注射液说明书探索灯盏细辛注射液临床用药的合理性与安全性.结果 120例接受灯盏细辛注射液治疗的患者中冠心病心绞痛47例(39.17%)、缺血性中风36例(30.00%)、椎-基底动脉供血不足性眩晕21例(17.5%)、心肌病11例(9.17%)、肺气肿肺部感染4例(3.33%)、腹股沟斜疝1例(0.83%).结合120例患者临床资料及灯盏细辛注射液的药物说明书,发现灯盏细辛注射液主要适用于存在血瘀证型的心脑血管疾病患者的疾病治疗,主要包括静脉、肌内和穴位注射三种给药方式;120例患者中89例(74.17%)患者治疗时间3-5天,21例(17.50%)患者治疗时间为6-7天,10例(8.33%)患者治疗时间为7-14天.结论 灯盏细辛注射液主要适用于存在血瘀证型的心脑血管疾病的治疗,如缺血性中风及脑出血后遗症、冠心病心绞痛患者、椎-基底动脉供血不足性眩晕、心肌病等,可有效促进患者局部血液循环恢复,改善患者临床症状.Objective To explore the rationality and safety of clinical medication of Erigeron breviscapus injection.Methods The clinical data of 120 patients treated with Erigeron breviscapus injection in our hospital from January 2021 to December 2021 were retrospectively analyzed.The clinical treatment data(disease type,condition,course of disease,dosage and method of Erigeron breviscapus injection,etc.)and basic data(age,gender,etc.)were systematically collected.The rationality and safety of clinical medication of Erigeron breviscapus injection were explored in combination with patient data and instructions of Erigeron breviscapus injection.Results Among the 120 patients treated with Erigeron breviscapus injection,there were 47 cases of angina pectoris(39.17%),36 cases of ischemic stroke(30.00%),21 cases of vertebrobasilar insufficiency vertigo(17.5%),11 cases of cardiomyopathy(9.17%),4 cases of emphysema and pulmonary infection(3.33%),and 1 case of indirect inguinal hernia(0.83%).Combined with the clinical data of 120 patients and the drug instructions of Erigeron breviscapus injection,it is found that Erigeron breviscapus injection is mainly suitable for the treatment of patients with cardiovascular and cerebrovascular diseases with blood stasis syndrome,mainly including intravenous,intramuscular and acupoint injection;among the 120 patients,89(74.17%)were treated for 3-5 days,21(17.50%)for 6-7 days,and 10(8.33%)for 7-14 days.Conclusion Erigeron breviscapus injection is mainly suitable for the treatment of cardiovascular and cerebrovascular diseases with blood stasis syndrome,such as ischemic stroke and sequelae of cerebral hemorrhage,patients with angina pectoris of coronary heart disease,vertebrobasilar insufficiency vertigo,cardiomyopathy,etc.it can effectively promote the recovery of local blood circulation and improve the clinical symptoms of patients.

关 键 词：灯盏细辛注射液 用药合理性 药物安全性 治疗药物 

分 类 号：R969.3[医药卫生—药理学]